安旭生物8月20日股价报42.05元，较前一交易日下跌1.20%。公司最新发布的2025年半年报显示，上半 年实现营收2.30亿元，扣非净利润2358.62万元，同比增长24.89%。 公司主营业务为POCT试剂及仪器的研发、生产与销售。报告期内，公司通过国际国内"双轮驱动"战 略，在海外市场不确定性增加的背景下，保持了经营韧性。国内市场方面，公司新获多项医疗器械注册 证，包括呼吸道病毒抗原检测笔、胸痛三联笔等产品。同时通过"安旭科"品牌开拓电商平台C端市场， 形成B端与C端双轨发展模式。 风险提示：投资有风险，入市需谨慎。公司面临海外市场政策变化、汇率波动等风险因素。 来源：金融界 ...

7月24日，安旭生物今日收盘41.19元，上涨2.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到33.53倍，总市值52.35亿元。 杭州安旭生物科技股份有限公司专注于POCT试剂及仪器的研发、生产与销售。公司主要产品为POCT 试剂及仪器。公司获评"浙江省知识产权示范企业"、"国家知识产权优势企业"。2024年,新增授权专利 44项,其中发明专利13项;累计获得授权专利305项,其中发明专利43项。获得欧盟CE认证、加拿大认证、 澳大利亚认证等多项权威认证证书,新增认证606项,其中,新增国际认证592项,新增国内认证14项,累计已 取得认证1580项。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物33.5327.221.0052.35亿行业平均 54.5649.684.73113.96亿行业中值37.5437.872.6253.43亿1九安医疗11.1011.220.87187.29亿2英科医疗 12.5613.541.12198.43亿3新华医疗15.6514.511.28100.34亿4奥美医疗16.1315.801.6658.26亿5振德医疗 16.161 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT reagents and instruments, and has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of March 31, 2025, Anxu Bio had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, Anxu Bio reported revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross profit margin of 42.32% [1] Market Position - Anxu Bio's current rolling price-to-earnings (PE) ratio is 30.51, while the average PE ratio for the medical device industry is 49.10, and the industry median is 36.43, placing Anxu Bio at the 69th position in the industry ranking [1][2] - The company's total market capitalization is 4.763 billion yuan [1][2] Intellectual Property and Certifications - In 2024, Anxu Bio added 44 new authorized patents, including 13 invention patents, bringing the total to 305 authorized patents, of which 43 are invention patents [1] - The company has obtained multiple authoritative certifications, including EU CE certification, Canadian certification, and Australian certification, with a total of 1,580 certifications, including 606 new certifications in the latest period [1]

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT (Point-of-Care Testing) reagents and instruments, with a product range covering eight major areas including drug detection, infectious disease detection, chronic disease detection, pregnancy detection, tumor detection, myocardial detection, biochemical detection, and allergen detection [1] - The company has developed a proprietary technology platform for antigen-antibody production and has established mature immunochromatography and dry biochemical diagnostic technology platforms [1] - Anxu Bio's products are exported to over 150 countries, including the USA, Germany, the UK, Canada, Russia, Mexico, Thailand, Indonesia, and Poland, positioning it as one of the few Chinese suppliers capable of competing with multinational in vitro diagnostic giants in the international POCT market [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, representing a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year [2] - The company's gross profit margin stands at 42.32% [2] Market Position - As of May 9, Anxu Bio's stock closed at 36.34 yuan, with a rolling price-to-earnings (PE) ratio of 29.58 times, and a total market capitalization of 4.618 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Anxu Bio at the 67th position in the industry ranking [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, including four funds, with a total holding of 50.38 million shares valued at 1.998 billion yuan [1]